|
08 Dec 2019 |
Curis Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax
|
|
08 Dec 2019 |
FDA Approves Amgen's AVSOLA™ (infliximab-axxq), For The Same Indications As Remicade® (infliximab)
|
|
08 Dec 2019 |
Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study
|
|
08 Dec 2019 |
Biohaven's Troriluzole Successfully Advances Past Interim Futility Analysis In Pivotal Phase 2/3 Alzheimer's Disease Study
|
|
08 Dec 2019 |
Denovo Biopharma Licenses Global Rights to a Novel Late-Stage Oncology Drug from Sunesis Pharmaceuticals
|
|
08 Dec 2019 |
Grifols presents its latest Alzheimer's clinical trial data
|
|
08 Dec 2019 |
Janssen to Acquire Investigational Bermekimab from XBiotech
|
|
08 Dec 2019 |
Cellular Biomedicine Group Presents First Clinical Data of IIT Phase 1 Trial of C-CAR088, a Novel BCMA CAR-T, at the 61st Annual Meeting of the American Society of Hematology
|
|
08 Dec 2019 |
First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
|
|
08 Dec 2019 |
MaaT Pharma Announces the Presentation of Positive Data with Its Lead Microbiome Biotherapeutic in Intestinal-Predominant Acute Graft-versus-Host-Disease at the ASH 2019 Annual Meeting
|
|
08 Dec 2019 |
Aleta Biotherapeutics Presents In Vivo Results of a Novel Therapeutic Designed to Reactivate CAR T Cells in Patients Who Relapse After CAR T Therapy
|
|
08 Dec 2019 |
Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment
|
|
08 Dec 2019 |
Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study
|
|
08 Dec 2019 |
Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome
|
|
08 Dec 2019 |
Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma
|
|
08 Dec 2019 |
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
|
|
08 Dec 2019 |
Genentech Announces New Data on Novel Cd20-cd3 Bispecific Cancer Immunotherapies in People With Difficult-to-Treat Lymphomas
|
|
08 Dec 2019 |
Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment
|
|
08 Dec 2019 |
ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)
|
|
08 Dec 2019 |
Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting
|
